Chemotherapy Agents in Older Cancer Patients
Author Information
Author(s): He Xiaoye, Clarke Stephen J., McLachlan Andrew J.
Primary Institution: Zhongshan Hospital, Fudan University; University of Sydney
Hypothesis
The study aims to identify and discuss the factors affecting the clinical pharmacology of chemotherapy agents in older people with cancer.
Conclusion
Age-related physiological changes significantly impact the pharmacokinetics and pharmacodynamics of cancer chemotherapy agents in older patients.
Supporting Evidence
- Older patients often have different responses to chemotherapy due to physiological changes.
- Comorbidities in older patients can complicate cancer treatment and increase risks.
- Individualized treatment plans are essential for older cancer patients to minimize toxicity.
Takeaway
As people get older, their bodies change, which can affect how cancer drugs work. This means doctors need to be careful when giving these drugs to older patients.
Methodology
The paper reviews existing studies and discusses the pharmacokinetics and pharmacodynamics of chemotherapy in older patients.
Potential Biases
Older patients are often excluded from clinical trials, leading to a lack of representative data for this demographic.
Limitations
The study highlights a lack of evidence-based guidelines for treating older cancer patients due to limited research in geriatric oncology.
Participant Demographics
The study focuses on older adults, particularly those aged 65 and older, with varying comorbidities.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website